Enhancing doxorubicin sensitivity in osteosarcoma via iRGD-modified biomimetic nanoparticles targeting MCAM m6A modification

Abstract Background Doxorubicin (Dox) resistance remains a significant challenge in osteosarcoma (OS) treatment, limiting its therapeutic efficacy and contributing to poor clinical outcomes. This study aims to investigate the use of iRGD-modified biomimetic nanoparticles (NPs) for the targeted deliv...

Full description

Bibliographic Details
Published in:Journal of Translational Medicine
Main Authors: Dongjian Song, Qiuliang Liu, Da Zhang, Zechen Yan, Meng Su, Qian Zhang, Hui Zhang, Longyan Shi, Yingzhong Fan, Heying Yang
Format: Article
Language:English
Published: BMC 2025-07-01
Subjects:
Osteosarcoma
Doxorubicin resistance
Nanotechnology
Methyltransferase 3
M6A modification
Melanoma cell adhesion molecule
Online Access:https://doi.org/10.1186/s12967-025-06735-5

Internet

https://doi.org/10.1186/s12967-025-06735-5

Similar Items